Midcareer Investigator Patient-oriented Research Award in Bronchiolitis & Asthma

职业生涯中期研究员毛细支气管炎患者导向研究奖

基本信息

  • 批准号:
    8443115
  • 负责人:
  • 金额:
    $ 10.83万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-03-15 至 2018-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Asthma is the result of host and environment interactions. Lower respiratory tract infections (LRTI), caused by viruses such as respiratory syncytial virus (RSV) and rhinovirus (RV), are a leading cause of bronchiolitis in infants. Infants hospitalized with bronchiolitis not only experience significant morbidity, but are also at significantly increased risk for both recurrent wheezing and childhood asthma. We have established that respiratory syncytial viral infections appear to directly contribute to asthma causation, not just simply identify persons at risk for subsequent wheezing. Viral infections outside the infant period are also important, as they are modifiable environmental factors that have been established to be the most common cause of asthma exacerbations in both children and adults. This proposal uses a combined, parallel clinical and experimental approach to evaluate the contribution of, causality, and mechanisms through which respiratory syncytial virus, and human rhinovirus, contribute to asthma development and disease natural history. These studies all relate to the central hypothesis that viruses, as one significant environmental factor, alter the risk for developing asthma, as well as the natural history of prevalent disease. Specific testable questions related to this hypothesis include: 1) to determine the host factors among those with RSV and HRV infection that contribute to asthma development, 2) to determine the timing of infection during infancy and how that impacts the risk of developing childhood asthma; 3) to determine the mechanisms through which RSV and HRV contribute to asthma development, specifically focusing on lung injury and differential immune response to infection; 4) to determine if there are allelic variations in host genes involved with severity of respiratory viral infection that correlate with a predisposition or resistance to both infant bronchiolitis and childhood asthma; 5) to determine if there are allelic variation in RSV genes that are associated with both infant LRTI severity, and subsequent risk of asthma development.
描述(由申请人提供):哮喘是宿主和环境相互作用的结果。由呼吸道合胞病毒(RSV)和鼻病毒(RV)等病毒引起的下呼吸道感染(LRTI)是婴儿毛细支气管炎的主要原因。婴儿 患有细支气管炎住院的患者不仅发病率很高,而且复发性喘息和儿童哮喘的风险也显着增加。我们已经确定呼吸道合胞病毒感染似乎直接导致哮喘的病因,而不仅仅是简单地识别出有随后喘息风险的人。婴儿期以外的病毒感染也很重要,因为它们是可改变的环境因素,已被确定为儿童和成人哮喘加重的最常见原因。该提案使用一种联合的、平行的临床和实验方法来评估呼吸道合胞病毒和人鼻病毒对哮喘发展和疾病自然史的贡献、因果关系和机制。这些研究都涉及到一个中心假设,即病毒作为一个重要的环境因素,改变了哮喘的发病风险,以及流行疾病的自然史。与该假设相关的具体可检验问题包括:1)确定RSV和HRV感染者中导致哮喘发展的宿主因素,2)确定婴儿期感染的时间以及如何影响儿童哮喘的风险; 3)确定RSV和HRV促进哮喘发展的机制,特别关注肺损伤和对感染的不同免疫反应; 4)确定在涉及呼吸道病毒感染严重性的宿主基因中是否存在等位基因变异,所述等位基因变异与婴儿细支气管炎和儿童哮喘的易感性或抗性相关; 5)确定RSV基因中是否存在与婴儿LRTI严重程度和随后的哮喘发展风险相关的等位基因变异。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Tina V Hartert其他文献

Tina V Hartert的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Tina V Hartert', 18)}}的其他基金

ECHO Renewal for the CANOE Study Cohort
CANOE 研究队列的 ECHO 更新
  • 批准号:
    10745082
  • 财政年份:
    2023
  • 资助金额:
    $ 10.83万
  • 项目类别:
Identifying Asthma-causing RSV Strains and Elucidating the Mechanisms of RSV-mediated Asthma Development
鉴定引起哮喘的 RSV 菌株并阐明 RSV 介导的哮喘发展机制
  • 批准号:
    10230392
  • 财政年份:
    2020
  • 资助金额:
    $ 10.83万
  • 项目类别:
Identifying Asthma-causing RSV Strains and Elucidating the Mechanisms of RSV-mediated Asthma Development
鉴定引起哮喘的 RSV 菌株并阐明 RSV 介导的哮喘发展机制
  • 批准号:
    10301922
  • 财政年份:
    2020
  • 资助金额:
    $ 10.83万
  • 项目类别:
Newborn Metabolic Screening for Prediction of Childhood Respiratory Phenotypes
新生儿代谢筛查用于预测儿童呼吸表型
  • 批准号:
    9090671
  • 财政年份:
    2016
  • 资助金额:
    $ 10.83万
  • 项目类别:
Newborn Metabolic Screening for Prediction of Childhood Respiratory Phenotypes
新生儿代谢筛查用于预测儿童呼吸表型
  • 批准号:
    9250797
  • 财政年份:
    2016
  • 资助金额:
    $ 10.83万
  • 项目类别:
Clinical Ascertainment, Biospecimen Acquisition, Data Management and Analysis Research Core
临床确定、生物样本采集、数据管理和分析研究核心
  • 批准号:
    10460524
  • 财政年份:
    2011
  • 资助金额:
    $ 10.83万
  • 项目类别:
Identifying Asthma-causing RSV Strains and Elucidating the Mechanisms of RSV-mediated Asthma Development
鉴定引起哮喘的 RSV 菌株并阐明 RSV 介导的哮喘发展机制
  • 批准号:
    9975086
  • 财政年份:
    2011
  • 资助金额:
    $ 10.83万
  • 项目类别:
Clinical Ascertainment, Biospecimen Acquisition, Data Management and Analysis Research Core
临床确定、生物样本采集、数据管理和分析研究核心
  • 批准号:
    10262868
  • 财政年份:
    2011
  • 资助金额:
    $ 10.83万
  • 项目类别:
RSV to Asthma Cooperative Clinical Ascertainment and Biospecimen Research Core
RSV 与哮喘合作临床确定和生物样本研究核心
  • 批准号:
    8196536
  • 财政年份:
    2011
  • 资助金额:
    $ 10.83万
  • 项目类别:
Clinical Ascertainment, Biospecimen Acquisition, Data Management and Analysis Research Core
临床确定、生物样本采集、数据管理和分析研究核心
  • 批准号:
    10675721
  • 财政年份:
    2011
  • 资助金额:
    $ 10.83万
  • 项目类别:

相似海外基金

A novel patient-facing mobile platform to collect and implement patient-reported outcomes and voice biomarkers in underserved adult patients with asthma
一种面向患者的新型移动平台,用于收集和实施服务不足的成年哮喘患者的患者报告结果和语音生物标志物
  • 批准号:
    10665856
  • 财政年份:
    2023
  • 资助金额:
    $ 10.83万
  • 项目类别:
Glucagon-Like Peptide-1 Receptor Agonist Treatment in Adult, Obesity-Related, Symptomatic Asthma
胰高血糖素样肽 1 受体激动剂治疗成人肥胖相关症状性哮喘
  • 批准号:
    10398799
  • 财政年份:
    2021
  • 资助金额:
    $ 10.83万
  • 项目类别:
Glucagon-Like Peptide-1 Receptor Agonist Treatment in Adult, Obesity-Related, Symptomatic Asthma
胰高血糖素样肽 1 受体激动剂治疗成人肥胖相关症状性哮喘
  • 批准号:
    10084583
  • 财政年份:
    2021
  • 资助金额:
    $ 10.83万
  • 项目类别:
Glucagon-Like Peptide-1 Receptor Agonist Treatment in Adult, Obesity-Related, Symptomatic Asthma
胰高血糖素样肽 1 受体激动剂治疗成人肥胖相关症状性哮喘
  • 批准号:
    10609049
  • 财政年份:
    2021
  • 资助金额:
    $ 10.83万
  • 项目类别:
Development of nurse-led support to enhance self-management in adult-onset asthma patients
开发护士主导的支持以加强成人哮喘患者的自我管理
  • 批准号:
    20K23142
  • 财政年份:
    2020
  • 资助金额:
    $ 10.83万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
CC16 in Childhood and Resilience to Persistent Asthma into Adult Life (Supplement)
CC16 在童年和成年生活中对持续性哮喘的抵抗力(补充)
  • 批准号:
    10189106
  • 财政年份:
    2020
  • 资助金额:
    $ 10.83万
  • 项目类别:
Investigating the Social Determinant and Developmental Risk Patterns in Childhood and Adolescence Associated with Adult Asthma and Diabetes Onset
调查儿童期和青少年期与成人哮喘和糖尿病发病相关的社会决定因素和发育风险模式
  • 批准号:
    450250
  • 财政年份:
    2020
  • 资助金额:
    $ 10.83万
  • 项目类别:
    Studentship Programs
Immunometabolic phenotypes in adult severe asthma and disease progression
成人严重哮喘和疾病进展的免疫代谢表型
  • 批准号:
    10896787
  • 财政年份:
    2019
  • 资助金额:
    $ 10.83万
  • 项目类别:
Immunometabolic phenotypes in adult severe asthma and disease progression
成人严重哮喘和疾病进展的免疫代谢表型
  • 批准号:
    10022504
  • 财政年份:
    2019
  • 资助金额:
    $ 10.83万
  • 项目类别:
Immunometabolic phenotypes in adult severe asthma and disease progression
成人严重哮喘和疾病进展的免疫代谢表型
  • 批准号:
    10684256
  • 财政年份:
    2019
  • 资助金额:
    $ 10.83万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了